Australia: Health hacking: Dealing with the cyber threat in digital health

Software and the electronic devices it controls, has become increasingly important in the healthcare industry over recent years. Digital health products, as they've come to be known, allow individuals to take a more active role in monitoring their health and fitness.

But as these devices continue to gain momentum, serious questions are being asked about the cyber security around them. First, can users be confident that their health information will be kept safe? And second, can users be confident that the device they're using will continue to work reliably? Clearly these questions are even more important in the case of devices where the consequences of compromised operation are potentially personal injury or death.

Both the Australian Therapeutic Goods Administration (TGA) and the United States Food & Drug Administration (FDA) regulate certain types of software as medical devices under their respective therapeutic goods regimes.

A key pre-market issue in the regulation of medical software is cyber security. Consideration of cyber security at the pre-market stage (i.e. during design and development) is vital to minimise the risk of a cyber security incident, and also to ensure that the device can be sold in Australia.

WHEN WILL SOFTWARE BE REGULATED AS A MEDICAL DEVICE?

In Australia medical devices are regulated under the Therapeutic Goods Act 1989 (Cth) (Therapeutic Goods Act).

Increasingly, devices falling under this legislation are being used to assist medical practitioners in their monitoring, diagnosis and treatment of their patients. Wearable devices, remote patient monitoring tools and sensors that track a patient's consumption of their medication are all examples of the growing application of digital technologies in the health sector.

Unless an exception applies, software will fall under the definition of a "medical device" if the manufacturer intends for it to be used in the diagnosis, prevention, monitoring, treatment or alleviation of a disease.1 This intention is ascertained from statements made by the manufacturer in labelling, instructions, advertising or in any other documentation about the software.2

For example, the following types of software are likely to be considered medical devices under the Therapeutic Goods Act:

  • mobile phone apps that measure a user's blood sugar level or blood pressure;
  • x-ray image processing software; and
  • diagnostic software.

Where an electronic device is controlled by such software, that device may (or may not) itself also be separately regulated as a medical device.

On the other hand, software that is only intended by the manufacturer to be used for presenting information (e.g. a health records management system or a dosage calculator) is unlikely to be treated as a medical device unless it incorporates a therapeutic function.3

CERTAIN SOFTWARE EXEMPTED FROM FDA REGULATION

While consideration of the "intended use" of a product allows the Therapeutic Goods Act to apply flexibly to new technology, it is not always clear whether certain types of software (especially software used for "low risk" therapeutic purposes) will be regulated under the Therapeutic Goods Act.

In the United States, greater clarity on this issue has recently emerged with the passing of legislation that expressly clarifies the scope of the definition of a medical device as it applies to software.

The 21st Century Cures Act ,4 which was signed into law on 13 December 2016, expressly exempts five categories of software from the definition of a medical device, being software which would otherwise fall within the definition of a medical device but which Congress has decided is low risk and will not be regulated as a medical device. These categories include:

  • software for transferring, storing or displaying medical information about an individual; and
  • software used to analyse medical information which also provides recommendations to a health care professional about the prevention, diagnosis or treatment of a disease. Importantly, the software cannot be designed such that the health care professional will primarily rely on any of the recommendations – the software must enable health care professionals to independently review the basis for each recommendation.

Software that falls within these exemptions is not subject to FDA regulation.

CYBER SECURITY RISKS FOR MEDICAL SOFTWARE

Given that medical software is often connected to the Internet or networked with other devices, cyber security is a critical consideration. It is also an issue that is receiving increased attention from the TGA and the FDA.

There are two key risks that need to be considered and managed in relation to the cyber security of medical software. The first is that sensitive health information may be lost or accessed by unauthorised parties. The second is that the function of the device could be compromised if there is a cyber security incident.

While many manufacturers of medical software appreciate their post-market cyber security obligations (e.g. to monitor their software and issue patches to solve defects and vulnerabilities), the pre-market requirements can often be overlooked.

Broadly, at the pre-market stage a manufacturer is required to take steps in its design of the software to mitigate the risk of a cyber security incident occurring throughout the lifecycle of the device (i.e. to both protect personal information and to protect the functionality of the device).

From a regulatory perspective, consideration of these cyber security risks is necessary to ensure that the device meets the "essential principles" for safety and performance as required under the Therapeutic Goods Act.5 A manufacturer must ensure that it has a record of the steps it has taken to ensure that the software complies with these essential principles.

For many devices, this information may need to be disclosed to the TGA as part of the conformity assessment process.

FAILURE TO TAKE ACCOUNT OF CYBER SECURITY

If a developer of medical software fails to properly design and build their product in a manner which takes account of their cyber security obligations:

  1. there is a risk that the device will not be permitted to be sold in Australia6;
  2. there is a risk that a manufacturer of a the device will contravene Australian Privacy Principle 11 for failing to implement reasonable steps to protect personal information from interference, loss or unauthorised access.7 A serious or repeated interference with privacy can lead to a civil penalty of up to $2.1 million.
  3. if the device is supplied in Australia, there is a risk that the manufacturer will contravene its obligations under the Therapeutic Goods Act, including the obligation not to supply a device that does not comply with the "essential principles".8 The maximum civil penalty for failing to comply with these requirements is $10.5 million.9

CYBER SECURITY – HOW CAN YOU GET IT RIGHT?

Consideration of cyber security at the design and development stage is vital. Not only will it ensure that the device can be legally supplied in Australia, it will also minimise the risk of non-compliance with the Therapeutic Goods Act and the Privacy Act 1988 (Cth).

The TGA recommends that software developers should perform risk assessments on their medical software as part of the design and development process by examining the specific clinical use of the software in the host environment.10

In order to demonstrate compliance with the essential principles for safety and performance under the Therapeutic Goods Act, developers should document their approach to cyber security in writing.

In general, relevant documents may include information about the way in which the software has been designed to ensure that the it secures and protects personal information from unauthorised access, and to ensure that the function of the software will not be adversely affected if it is subject to a cyber security incident.

The TGA hasn't published specific guidance about the information it requires in relation to cyber security. However, we expect that high risk medical devices (i.e. those used to treat or diagnose serious diseases) will need more information than lower risk devices to confirm that the software meets the essential principles.

The position in the United States regarding documenting the approach to cyber security is clearer. The FDA's (non-binding) guidance document "Content of Premarket Submissions for Management of Cybersecurity in Medical Devices" recommends that manufacturers keep a record of the following:11

  • hazard analysis, mitigations, and design considerations regarding intentional and unintentional cyber security risks and controls of the medical device;
  • a traceable matrix that links actual cyber security controls to the cyber security risks considered;
  • a summary of the plan to provide patches and software updates as needed throughout the lifecycle of the medical device to continue to assure its safety and effectiveness;
  • a summary describing the controls that are in place to ensure that the medical device will maintain its integrity (including that it will be free of malware);
  • device instructions for use and product specifications related to recommended cyber security controls appropriate for the intended use environment; and
  • a record of the design/bug log may also be useful for higher risk medical software.

Manufacturers of medical software that have not addressed and documented these issues in the design of their product risk the device not being cleared for sale in the United States.

KEY CONSIDERATIONS FOR SOFTWARE DEVELOPERS

When designing software, developers should consider whether their software will be regulated as a medical device under the Therapeutic Goods Act. Indeed, developers should consider at the outset how the claims they make about their software and their instructions for the use of their software might affect the way in which their product is regulated in relevant markets.

If the software is a medical device, developers must consider and document their approach to cyber security. This should occur at an early stage of the design and development process.

Although the FDA's guidance on premarket documentation is not binding in Australia, developers of medical software should be aware of its existence. The guidance will be of critical importance to Australian software developers looking to take their software to the United States market. The guidance also provides a useful insight into the types of information that the TGA may consider relevant to demonstrating that the software complies with the essential principles.

Footnotes

1 Therapeutic Goods Act 1989 (Cth) s 41BD(1)(a).

2 Ibid s 41BD(2).

3 Therapeutic Goods Administration, 'Regulation of medical software and mobile medical 'apps'', 13 September 2013 < https://www.tga.gov.au/regulation-medical-software-and-mobile-medical-apps >.

4 21st Century Cures Act, Pub. L. No. 114-255, 130 Stat. 1033.

5 Therapeutic Goods Act 1989 (Cth) ss 41MA and 41MAA; Therapeutic Goods (Medical Devices) Regulations) 2002 (Cth) sch 1.

6 See e.g. Therapeutic Goods Act 1989 (Cth) s 41ME.

7 Privacy Act 1988 (Cth) sch 1, APP 11 "security of personal information".

8 Therapeutic Goods Act 1989 (Cth) ss 41MA and 41MAA.

9 Ibid.

10 Therapeutic Goods Administration, 'Medical Devices Safety Update' Vol 4(2), 2 March 2016 "Device cyber security a key issue" < HTTPS://WWW.TGA.GOV.AU/PUBLICATION-ISSUE/MEDICAL-DEVICES-SAFETY-UPDATE-VOLUME-4-NUMBER-2-MARCH-2016#DEVICE-CYBER SECURITY >.

11 Food & Drug Administration of America "Content of Premarket Submissions for Management of Cyber security in Medical Devices" 2 October 2014 < HTTPS://WWW.FDA.GOV/DOWNLOADS/MEDICALDEVICES/DEVICEREGULATIONANDGUIDANCE/GUIDANCEDOCUMENTS/UCM356190.PDF >.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Chambers Asia Pacific Awards 2016 Winner – Australia
Client Service Award
Employer of Choice for Gender Equality (WGEA)

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions